About Kaival Labs
Kaival Labs is a company based in Palm Bay (United States) founded in 2019. It operates as a B2C. Kaival Labs operates in a competitive market with competitors including Indivior, Ethypharm, IgGenix, Braeburn and Cessation Therapeutics, among others.
- Headquarter Palm Bay, United States
- SectorsHealthcare
- Website kaivallabs.com
- Social X Facebook
Competitors of Kaival Labs
Kaival Labs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Ethypharm, IgGenix, Braeburn and Cessation Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.1M | – | Therapies for pain and addiction treatment are developed. | |
| iggenix.com | 2019 | San Francisco, United States | $75.0M | – | Therapeutic solutions for food allergies are developed via antibody platforms. | |
| braeburnrx.com | 2012 | Philadelphia, United States | $110.0M | – | Long-acting therapies for opioid addiction and chronic pain are developed. | |
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.8M | – | Developer of immunotherapy based vaccines to manage addictions | |
| amygns.com | 2015 | San Francisco, United States | $7.0M | – | Therapies for substance use disorders are developed by Amygdala Neurosciences. | |
| aelisfarma.com | 2013 | Bordeaux, France | $14.0M | – | Developer of small molecule drugs targeting CB1 receptor for CNS diseases | |
| titanpharm.com | 1992 | San Francisco, United States | – | 11 | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | |
| 4p-pharma.com | 2014 | Lille, France | $18.5M | – | French Biotech startup that develops to clinical trial stage the molecules it has in-licensed | |
| biotie.com | 1998 | Turku, Finland | $149.8M | 27 | Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. |
Detailed competitors of Kaival Labs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kaival Labs
Complete news archive for Kaival Labs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Kaival Labs
10 companies that operate in the same segment as Kaival Labs (Pain Management), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | – | 24 | |
Pain treatment products are developed through reformulation technologies. | 2007 | Herzliya, Central District, Israel | USD 12 M | USD 17 K | 6 | |
Drug delivery systems for CNS disorders and pain are developed. | 2006 | Emeryville, California, United States | USD 149.06 M | – | – | |
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment | 2010 | Bloomington, Indiana, United States | USD 530 M | USD 91.65 M | – | |
Therapies for pain and addiction treatment are developed. | 1977 | Saint-cloud, France | USD 248.09 M | USD 167.87 M | – | |
Novel drug products for chronic pain treatment are developed. | 2007 | Blue Bell, Pennsylvania, United States | USD 12.96 M | – | 17 | |
Abuse-deterrent extended-release therapeutics for chronic pain are developed. | 2002 | Canton, Ohio, United States | USD 103 M | USD 780.57 M | 357 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Kaival Labs
Kaival Labs was founded in 2019.
Kaival Labs is headquartered in Palm Bay, United States. It is registered at Palm Bay, Florida, United States.
Kaival Labs develops innovative technologies for nicotine addiction treatment through providing healthcare solutions, developing medical devices, addiction treatment, and nicotine cessation. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.